Karen Lackey

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +14

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

David W. Rusnak, Karen Lackey, Karen Affleck et al. · PubMed · 2001 · 738 citations

Medicine, Oncology, Pharmacology +17

Comprehensive characterization of the Published Kinase Inhibitor Set

Jonathan M. Elkins, Vita Fedele, M. Szklarz et al. · Nature Biotechnology · 2015 · 350 citations

Pharmacy, Medicinal Chemistry, Oncology +13

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

David W. Rusnak, Karen Affleck, Stuart Cockerill et al. · PubMed · 2001 · 297 citations

Medicine, Oncology, Pharmacology +15

Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2):  Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis

H. Neal Bramson, J. Corona, Stephen T. Davis et al. · Journal of Medicinal Chemistry · 2001 · 271 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17